LP 0128
Alternative Names: LP-0128Latest Information Update: 09 Sep 2024
At a glance
- Originator LEO Pharma
- Class Antipsoriatics; Small molecules
- Mechanism of Action IL17A protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 28 Apr 2024 Discontinued - Preclinical for Psoriasis in Denmark (PO)
- 30 Aug 2023 LP 0128 is available for licensing as of 30 Aug 2023. https://www.leo-pharma.com/partnership (Leo Pharma website; August 2023)
- 26 Aug 2023 Preclinical trials in Psoriasis in Denmark (PO) (LEO Pharma pipeline; August 2023)